Equities

CNSP

US18978H2013

Delayed Nasdaq Other stock markets 12:20:32 2024-06-03 pm EDT			5-day change	1st Jan Change
0.1479 ^USD	-31.59%		-28.21%	-88.42%

05:21pm	CNS Pharmaceuticals Schedules 1-For-50 Reverse Stock Split This Week	MT
May. 15	CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 31, 2023 at 05:04 pm EDT

CNS Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 15.27 million compared to USD 14.5 million a year ago. Basic loss per share from continuing operations was USD 11.22 compared to USD 16.5 a year ago.

Diluted loss per share from continuing operations was USD 11.22 compared to USD 16.5 a year ago.

Latest news about CNS PHARPAR

CNS Pharmaceuticals Schedules 1-For-50 Reverse Stock Split This Week	11:21am	MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
CNS Pharmaceuticals, Inc. Announces Committee Changes	May. 03	CI
Transcript : CNS Pharmaceuticals, Inc. - Shareholder/Analyst Call	Apr. 30
Transcript : CNS Pharmaceuticals, Inc. - Special Call	Apr. 23
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees	Feb. 27	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	Jan. 30	MT
CNS Pharmaceuticals Prices $4 Million Offering; Shares Fall Pre-Bell	Jan. 30	MT
CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors	Jan. 18	CI
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	Jan. 17	CI
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	Dec. 18	CI
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	Nov. 22	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : CNS Pharmaceuticals, Inc. - Pre Recorded Special Call	23-10-17
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland	23-10-11	CI
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme	23-09-07	CI
CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy	23-08-14	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme	23-08-03	CI
Top Premarket Gainers	23-05-22	MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors	23-05-08	CI
Transcript : CNS Pharmaceuticals, Inc. - Special Call	23-05-03
Top Premarket Gainers	23-04-20	MT

Chart CNS PHARPAR

Duration

Period

More charts

Company Profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Sector

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar